Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe : multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 27(2022), 21 vom: 27. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kissling, Esther [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 30.05.2022 Date Revised 27.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2022.27.21.2101104 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34143325X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34143325X | ||
| 003 | DE-627 | ||
| 005 | 20231226011753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2022.27.21.2101104 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM34143325X | ||
| 035 | |a (NLM)35620997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kissling, Esther |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe |b multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2022 | ||
| 500 | |a Date Revised 27.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Delta variant | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a multicentre study | |
| 650 | 4 | |a test-negative design | |
| 650 | 4 | |a vaccine effectiveness | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Hooiveld, Mariëtte |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Baz, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Mazagatos, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a William, Naoma |e verfasserin |4 aut | |
| 700 | 1 | |a Vilcu, Ana-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Kooijman, Marjolein N |e verfasserin |4 aut | |
| 700 | 1 | |a Ilić, Maja |e verfasserin |4 aut | |
| 700 | 1 | |a Domegan, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Ausenda |e verfasserin |4 aut | |
| 700 | 1 | |a de Lusignan, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, Mihaela |e verfasserin |4 aut | |
| 700 | 1 | |a Meijer, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Brytting, Mia |e verfasserin |4 aut | |
| 700 | 1 | |a Casado, Itziar |e verfasserin |4 aut | |
| 700 | 1 | |a Larrauri, Amparo |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Josephine-L K |e verfasserin |4 aut | |
| 700 | 1 | |a Behillil, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a de Gier, Brechje |e verfasserin |4 aut | |
| 700 | 1 | |a Mlinarić, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Ana Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Tsang, Ruby |e verfasserin |4 aut | |
| 700 | 1 | |a Timnea, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a de Lange, Marit |e verfasserin |4 aut | |
| 700 | 1 | |a Riess, Maximilian |e verfasserin |4 aut | |
| 700 | 1 | |a Castilla, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Pozo, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Falchi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Knol, Mirjam J |e verfasserin |4 aut | |
| 700 | 1 | |a Kurečić Filipović, Sanja |e verfasserin |4 aut | |
| 700 | 1 | |a Dunford, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Guiomar, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Cogdale, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Cherciu, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Tessa |e verfasserin |4 aut | |
| 700 | 1 | |a Enkirch, Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Basile, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Connell, Jeff |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Sandonis Martín, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Bacci, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Rose, Angela Mc |e verfasserin |4 aut | |
| 700 | 1 | |a Pastore Celentano, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Valenciano, Marta |e verfasserin |4 aut | |
| 700 | 0 | |a I-MOVE-COVID-19 and ECDC primary care study teams |e verfasserin |4 aut | |
| 700 | 0 | |a I-MOVE-COVID-19 and ECDC primary care study team (in addition to authors above) |e verfasserin |4 aut | |
| 700 | 1 | |a Čusek Adamić, Katica |e investigator |4 oth | |
| 700 | 1 | |a Ferenčak, Ivana |e investigator |4 oth | |
| 700 | 1 | |a Kaić, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Kosanović Ličina, Mirjana Lana |e investigator |4 oth | |
| 700 | 1 | |a Lakošeljac, Danijela |e investigator |4 oth | |
| 700 | 1 | |a Mihin Huskić, Ivana |e investigator |4 oth | |
| 700 | 1 | |a Nonković, Diana |e investigator |4 oth | |
| 700 | 1 | |a Andrews, Nick |e investigator |4 oth | |
| 700 | 1 | |a Lopez Bernal, Jamie |e investigator |4 oth | |
| 700 | 1 | |a Ellis, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Whitaker, Heather |e investigator |4 oth | |
| 700 | 1 | |a Blanchon, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Guerrisi, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Launay, Titouan |e investigator |4 oth | |
| 700 | 1 | |a Masse, Shirley |e investigator |4 oth | |
| 700 | 1 | |a van der Werf, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Enouf, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Cuddihy, John |e investigator |4 oth | |
| 700 | 1 | |a O'Connor, Lois |e investigator |4 oth | |
| 700 | 1 | |a McKenna, Adele |e investigator |4 oth | |
| 700 | 1 | |a Joyce, Michael |e investigator |4 oth | |
| 700 | 1 | |a de Gascun, Cillian |e investigator |4 oth | |
| 700 | 1 | |a Moran, Joanne |e investigator |4 oth | |
| 700 | 1 | |a van Gageldonk-Lafeber, Rianne |e investigator |4 oth | |
| 700 | 1 | |a Hahné, Susan J |e investigator |4 oth | |
| 700 | 1 | |a de Melker, Hester E |e investigator |4 oth | |
| 700 | 1 | |a Fanoy, Ewout B |e investigator |4 oth | |
| 700 | 1 | |a Raven, Stijn |e investigator |4 oth | |
| 700 | 1 | |a Middeldorp, Marit |e investigator |4 oth | |
| 700 | 1 | |a Kislaya, Irina |e investigator |4 oth | |
| 700 | 1 | |a Nunes, Baltazar |e investigator |4 oth | |
| 700 | 1 | |a Roquete, Rita |e investigator |4 oth | |
| 700 | 1 | |a Silva, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Melo, Aryse |e investigator |4 oth | |
| 700 | 1 | |a Costa, Inês |e investigator |4 oth | |
| 700 | 1 | |a Verdasca, Nuno |e investigator |4 oth | |
| 700 | 1 | |a Conde, Patrícia |e investigator |4 oth | |
| 700 | 1 | |a Soeiro, Amélia |e investigator |4 oth | |
| 700 | 1 | |a Mihai, Maria Elena |e investigator |4 oth | |
| 700 | 1 | |a Bistriceanu, Iulia |e investigator |4 oth | |
| 700 | 1 | |a Ivanciuc, Alina |e investigator |4 oth | |
| 700 | 1 | |a Dintoi, Diana |e investigator |4 oth | |
| 700 | 1 | |a Pascu, Catalina |e investigator |4 oth | |
| 700 | 1 | |a Jidovu, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Sigerson, Debbie |e investigator |4 oth | |
| 700 | 1 | |a Marques, Diogo Fp |e investigator |4 oth | |
| 700 | 1 | |a Molesworth, Anna |e investigator |4 oth | |
| 700 | 1 | |a Quinn, Leanne |e investigator |4 oth | |
| 700 | 1 | |a Leyton, Miranda |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Selin |e investigator |4 oth | |
| 700 | 1 | |a Thoulass, Janine |e investigator |4 oth | |
| 700 | 1 | |a McMenamin, Jim |e investigator |4 oth | |
| 700 | 1 | |a Casas Flecha, Inmaculada |e investigator |4 oth | |
| 700 | 1 | |a Martínez Mateo, Ana |e investigator |4 oth | |
| 700 | 1 | |a Castrillejo, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Martínez Ochoa, Eva María |e investigator |4 oth | |
| 700 | 1 | |a Quiñones Rubio, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Delgado-Sanz, Concepción |e investigator |4 oth | |
| 700 | 1 | |a Oliva, Jesús |e investigator |4 oth | |
| 700 | 1 | |a Miqueleiz, Ana |e investigator |4 oth | |
| 700 | 1 | |a Navascués, Ana |e investigator |4 oth | |
| 700 | 1 | |a Trobajo-Sanmartín, Camino |e investigator |4 oth | |
| 700 | 1 | |a Ezpeleta, Carmen |e investigator |4 oth | |
| 700 | 1 | |a López Moreno, Paula |e investigator |4 oth | |
| 700 | 1 | |a Gorricho, Javier |e investigator |4 oth | |
| 700 | 1 | |a Ardanaz, Eva |e investigator |4 oth | |
| 700 | 1 | |a Baigorria, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Barricarte, Aurelio |e investigator |4 oth | |
| 700 | 1 | |a Burgui, Cristina |e investigator |4 oth | |
| 700 | 1 | |a de la Cruz, Enrique |e investigator |4 oth | |
| 700 | 1 | |a Egüés, Nerea |e investigator |4 oth | |
| 700 | 1 | |a García Cenoz, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Guevara, Marcela |e investigator |4 oth | |
| 700 | 1 | |a Moreno-Iribas, Conchi |e investigator |4 oth | |
| 700 | 1 | |a Sayón, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Penttinen, Pasi |e investigator |4 oth | |
| 700 | 1 | |a Carstairs, Christiana |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 27(2022), 21 vom: 27. Mai |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:21 |g day:27 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2022.27.21.2101104 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 21 |b 27 |c 05 | ||